Study identification

PURI

https://redirect.ema.europa.eu/resource/104306

EU PAS number

EUPAS104305

Study ID

104306

Official title and acronym

Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers

DARWIN EU® study

No

Study countries

France
Germany
United Kingdom

Study description

A descriptive study of the yearly prevalence of primary and secondary arterial hypertension in children and their treatment with angiotensin II receptor blockers

Study status

Finalised
Research institution and networks

Institutions

Contact details

Karin Hedenmalm

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
EMA
Study protocol
Initial protocol

Analysis Plan_Arterial hypertension and ARBs use in children - For publication_CLEAN

English (485.51 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable